Riley, Megan
Lambrelli, Dimitra
Graham, Sophie
Henry, Ouzama
Sutherland, Andrea
Schmidt, Alexander
Sawalhi-Leckenby, Nicola
Donaldson, Robert
Stoszek, Sonia K.
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Received: 7 September 2022
Accepted: 11 April 2023
First Online: 9 May 2023
Declarations
:
: CPRD obtained ethics approval to receive and supply patient data for public health research (ExternalRef removed). The protocol of this retrospective observational cohort study was approved by the Independent Scientific Advisory Committee (ISAC) for research involving CPRD data (protocol no. 18_144RA) and has been made available to the journal reviewers. All methods were carried out in accordance with relevant guidelines and regulations. As per CPRD (ExternalRef removed), no information that can identify a patient is ever sent to CPRD; CPRD never receives any patient identifiers from a general practitioner (GP) practice such as patient name, address, NHS number, full date of birth or medical notes; and because a patient cannot be identified from data a GP practice sends to CPRD, ISAC does not require the GP practice to seek a patient’s consent to share data with CPRD.This study is based on data from the Clinical Practice Research Datalink (CPRD) obtained under license from the United Kingdom Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the National Health Service (NHS) as part of their care and support. The interpretation and conclusions contained in this report are those of the authors alone.
: Not applicable.
: MR and OH are employees of the GSK group of companies (GSK). ASc, ASu, and SS were GSK employees at the time of the study. OH, ASc, and SS own GSK stocks or shares. DL, SG, NSL, and RD are salaried employees of Evidera, the consultancy company hired by GSK to perform this work. The authors declare no other financial or non-financial interests.